US Pharma MarketingThe post Caliway secures FDA clearance for CBL-514 clinical trial appeared first on Clinical Trials Arena.
Caliway secures FDA clearance for CBL-514 clinical trial
Caliway Biopharmaceuticals has received the US FDA clearance for its CBL-0302 IND application, enabling a pivotal Phase III clinical trial of CBL-514 for abdominal subcutaneous fat reduction. Caliway intends to commence both pivotal Phase III trials soon, with clinical results for CBL-0301 and CBL-0302 expected in 2027. CBL-0302 trial will assess the safety, tolerability, and efficacy of CBL-514 injections. Credit: PhotobyTawat/Shutterstock.com. Caliway Biopharmaceuticals has received the US Food and Drug Administration (FDA) clearance for its CBL-0302 Investigational New Drug (IND) application, enabling a pivotal Phase III clinical trial of CBL-514 for abdominal subcutaneous fat reduction. This follows the completion of…
Caliway Biopharmaceuticals has received the US FDA clearance for its CBL-0302 IND application, enabling a pivotal Phase III clinical trial of CBL-514 for abdominal subcutaneous fat reduction.
Source: Clinical Trials Arena